Gossamer Bio Net Tangible Assets History
| GOSS Stock | USD 0.37 -0.02 -5.13% |
Net Tangible Assets | First Reported 2018-03-31 | Previous Quarter -28.5 M | Current Value -62.8 M | Quarterly Volatility 199.7 M |
Macro event markers
Latest Gossamer Bio Net Tangible Assets Growth Pattern
| Net Tangible Assets | 10 Years Trend |
|
Net Tangible Assets |
| Timeline |
Net Tangible Assets Trend Statistics
The coefficient of variation for Gossamer Bio's Net Tangible Assets stands at 276.6%, reflecting elevated dispersion relative to the mean across 8 periods. With an R-squared of 0.03, the data suggests no statistically meaningful linear trend.| Arithmetic Mean | 42,950,216 | |
| Coefficient Of Variation | 276.56 | |
| Mean Deviation | 78,327,218 | |
| Median | -123,000 | |
| Standard Deviation | 118,781,628 | |
| Sample Variance | 14109.1T | |
| Range | 472.6M | |
| R-Value | 0.18 | |
| Mean Square Error | 14547.4T | |
| R-Squared | 0.03 | |
| Significance | 0.48 | |
| Slope | 4,297,394 | |
| Total Sum of Squares | 225745.2T |
Gossamer Bio Net Tangible Assets History
Gossamer Bio's Net Tangible Assets is tracked from 2017 through 2026, spanning 8 reported values, moving from -6.9 M to 13.2 M.Correlation of Net Tangible Assets With Other Accounts
The table presents linear correlations between Gossamer Bio's Net Tangible Assets and adjacent financial accounts. Positive values indicate co-directional movement; negative values indicate inverse movement. These relationships describe association, not causation.Related Fundamentals
| Last Reported | End Of Year Estimate | ||
| Return On Tangible Assets | -0.99 | -1.04 | |
| Tangible Book Value Per Share | -0.54 | -0.51 |
Methodology, Assumptions & Data Sources
The historical progression of Gossamer Bio's Net Tangible Assets is shown below. Cross-referencing this metric with adjacent financial statement accounts provides additional explanatory context. Gossamer Bio's Net Tangible Assets is shaped by investment and capital allocation patterns characteristic of the Biotechnology sector.
Gossamer Bio analytics rely on periodic company reporting and market reference feeds, with quality checks and normalization applied. Reference data and historical patterns are presented and do not constitute an investment recommendation or advice.
Editorial review and methodology oversight provided by: Rifka Kats, Member of Macroaxis Editorial Board